ADARx Pharmaceuticals
RNA-based therapeutics using proprietary targeted delivery platforms to silence disease-causing genes
- Sector
- Biotech
- Headquarters
- San Diego, CA
- Founded
- 2019
- Latest Form D
- $200M, Aug 2023
- Total capital
- $353M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $353M
- 7 Form D · last Aug 2023
- 39 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 38 pending · first 2024
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$200M
- Private capital raisedForm D · SEC · 6th filing$46M
- Private capital raisedForm D · SEC · 5th filing$75M
- Private capital raisedForm D · SEC · 4th filing$15.5M
- Private capital raisedForm D · SEC · 3rd filing$6M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Private capital raisedForm D · SEC · 1st filing$5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carl GordonDirectorNamed in SEC Form D filings
- Chen YuDirectorNamed in SEC Form D filings
- Erez ChimovitsDirectorNamed in SEC Form D filings
- Hongbo LuDirectorNamed in SEC Form D filings
- Judith LiDirectorNamed in SEC Form D filings
- Lorence KimDirectorNamed in SEC Form D filings
Show all 14 people
- Ricky SunDirectorNamed in SEC Form D filings
- Rui ZhuExecutive OfficerNamed in SEC Form D filings
- Sheila GujrathiDirectorNamed in SEC Form D filings
- Simeon GeorgeDirectorNamed in SEC Form D filings
- Xiong ZhangDirectorNamed in SEC Form D filings
- Yuan (Eliza) SunDirectorNamed in SEC Form D filings
- Yuan SunDirectorNamed in SEC Form D filings
- Zhen LiExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 40- PendingPrekallikrein-modulating Compositions And Methods Of Use ThereofUSPTOApplication 19681713
- PendingComplement Factor B-modulating Compositions And Methods Of Use ThereofUSPTOApplication 18713250
- PendingAngiotensinogen-modulating Compositions And Methods Of Use ThereofUSPTOApplication 19630043
Show all 40 patent records
- Prekallikrein-modulating Compositions And Methods Of Use ThereofSep 17, 2026 · Application 19681713Pending
- Complement Factor B-modulating Compositions And Methods Of Use ThereofSep 3, 2026 · Application 18713250Pending
- Angiotensinogen-modulating Compositions And Methods Of Use ThereofAug 6, 2026 · Application 19630043Pending
- CB1 Ligand Conjugated Compounds And Uses ThereofJun 25, 2026 · Application 18842673Pending
- Complement Factor B-modulating Compositions And Methods Of Use ThereofApr 7, 2026 · US 12,595,477Granted
- a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOFJan 1, 2026 · Application 18852103Pending
- Oligonucleotides Having A Synthetic Backbone And Synthesis ThereofOct 9, 2025 · Application 18865220Pending
- Trkb Ligand Conjugated Compounds And Uses ThereofMay 22, 2025 · Application 18837377Pending
- Prekallikrein-modulating Compositions And Methods Of Use ThereofApr 10, 2025 · Application 18697180Pending
- Prekallikrein-modulating Compositions And Methods Of Use ThereofMar 6, 2025 · Application 18673525Pending
- Angiotensinogen-modulating Compositions And Methods Of Use ThereofDec 5, 2024 · Application 18697165Pending
- Prekallikrein-modulating Compositions And Methods Of Use ThereofJul 23, 2024 · US 12,042,509Granted
- Rna Silencing Agents And Methods Of UseJun 13, 2024 · Application 18286640Pending
- N-acetylgalactosamine (galnac)-derived Compounds And OligonucleotidesMar 14, 2024 · Application 18030968Pending
- Angiotensinogen-modulating Compositions And Methods Of Use ThereofFeb 8, 2024 · Application 18194203Pending
- Pharmaceutical Agent-integrin Ligand Conjugates For Muscle DeliveryApplication PCTUS2024050986Pending
- Mapt-modulating Oligonucleotides For Treating Central Nervous System DiseasesApplication 63711676Pending
- Mannose Receptor Ligand-tropomyosin Receptor B Ligand Conjugates For Drug DeliveryApplication PCTUS2025020900Pending
- Perilipin 1 (PLIN1)-MODULATING Compositions And Methods Of Use ThereofApplication 63715296Pending
- Coagulation Factor Xi-modulating Compositions And Methods Of Use ThereofApplication PCTUS2024038771Pending
- Cannabinoid Receptor 1 (CB1)-MODULATING Compositions And Methods Of Use ThereofApplication PCTUS2025047739Pending
- Nmda Ligand Conjugated Compounds And Uses ThereofApplication 19483386Pending
- Oligonucleotides Containing A Ligand At An Internal PositionApplication PCTUS2024042764Pending
- Oligonucleotides Containing A Ligand At A Nucleobase, 2' Position, Or 3' PositionApplication PCTUS2024042786Pending
- SOD1-MODULATING Oligonucleotides For Treating Central Nervous System DiseasesApplication 63723269Pending
- Modified Oligonucleotides Containing Multiple OligonucleotidesApplication PCTUS2024042783Pending
- Amyloid Precursor Protein-modulating Compositions And Methods Of Use ThereofApplication PCTUS2026018138Pending
- Complement Component 3 (C3)-MODULATING Compositions And Methods Of Use ThereofApplication PCTUS2026016099Pending
- LRRK2-MODULATING Compositions And Methods Of Use ThereofApplication 19495166Pending
- Amyloid Precursor Protein-modulating Compositions And Methods Of Use ThereofApplication 63768244Pending
- Oligonucleotides Containing Multiple Ligands And/or LipidsApplication PCTUS2024042772Pending
- Alpha-synuclein-modulating Compositions And Methods Of Use ThereofApplication 63730894Pending
- Mapt-modulating Oligonucleotides For Treating Central Nervous System DiseasesApplication PCTUS2025052172Pending
- Nmda Ligand Conjugated Compounds And Uses ThereofApplication PCTUS2024028958Pending
- Prekallikrein-modulating Compositions And Methods Of Use ThereofApplication 18667488Pending
- SOD1-MODULATING Compositions And Methods Of Use ThereofApplication PCTUS2024031069Pending
- Cannabinoid Receptor 1 (CB1)-MODULATING Compositions And Methods Of Use ThereofApplication 63698313Pending
- Mapt-modulating Compositions And Methods Of Use ThereofApplication PCTUS2024025577Pending
- Complement Factor B-modulating Compositions And Methods Of Use ThereofApplication PCTUS2024060424Pending
- LRRK2-MODULATING Compositions And Methods Of Use ThereofApplication PCTUS2024034695Pending
Related companies, and why
- SANARENTERO LLCSimilar federal contract value in Biotech · null in contracts
- KARYOPHARM THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Umoja BiopharmaSimilar federal contract value in Biotech · null in contracts
- COARE HOLDINGS INCSimilar federal contract value in Biotech · null in contracts
- Reservoir Neuroscience, Inc.Similar federal contract value in Biotech · null in contracts
- Carmot Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .